Background about Glioblastoma
At diagnosis, the standard treatment is largely confined to surgery, radiation and Temodar with median time until disease progression/recurrence under this standard protocol is 7 months.
The total median survival is 14-15 months. This poses an urgent need for novel treatment options for patients.
Keppra is a well established medication used to treat epilepsy.
About KBTS-1601 study
These results will be presented during weekend at the American Society of Clinical Oncology, ASCO, annual meeting, May 29 – June 2, 2020.
Study data were compared to data from another study were patients did not receive Keppra, but received radiotherapy and Temodar as in this study. This way the researchers had a controlled group to compare to their results.
46 patients were enrolled to the study. All patients completed standard radiation therapy with Temodar and 39 patients completed 6 cycles of adjuvant Temodar.
- Median survival was almost doubled and reached 30 months
- Median time until the disease had progressed/recurred was prolonged to 15 months
- Percentage of patients alive at 6, 12, and 24 months was 100%, 91.3%, and 60.7%, respectively
- Percentage of patients without disease had progressed/recurred at 6, 12, and 24 months was 93.2%, 65.3%, and 22.6%, respectively.
What is the conclusion for Glioblastoma patients?
Addition of Keppra during concurrent and adjuvant Temodar along with radiotherapy in patients with newly diagnosed Glioblastoma, GBM, may result in improved outcomes compared to standard therapy alone.
Contact us to find out what is the best treatment for YOU
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039